Trials / Completed
CompletedNCT04589013
Prediction of Response to Treatment With Immunotherapy + Chemotherapy in Non-Small Cell Lung Cancer
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 106 (actual)
- Sponsor
- University Hospital, Lille · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study seeks to evaluate a multiparametric test including 6 immunohistochemical markers (PD-L1, CD8, FoxP3, PD1, CD163, CD15) to predict the cumulative incidence of death or progression on treatment with pembrolizumab+first line chemotherapy in metastatic non-small cell lung cancer, regardless of the PD-L1 status and in the absence of ALK, ROS1 or EGFR alteration.
Conditions
Timeline
- Start date
- 2020-11-19
- Primary completion
- 2023-09-29
- Completion
- 2023-09-29
- First posted
- 2020-10-19
- Last updated
- 2025-12-23
Locations
4 sites across 1 country: France
Source: ClinicalTrials.gov record NCT04589013. Inclusion in this directory is not an endorsement.